 |
 |

Hypothalamic-Pituitary-Adrenal Axis Suppression in Systemic Glucocorticoid-Treated Infantile HemangiomasPutting the Risk Into Context
Robert Sidbury, MD, MPH
Arch Dermatol. 2009;145(3):319-320.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
Hemangiomas of infancy (IH) are the most common benign tumor of childhood.1 When small and located in nonvital areas, IH may be safely observed; however, approximately 10% to 20% become "problematic" and require intervention (Figure).2 The gold standard therapy is systemic glucocorticoids (GCs).3 Glucocorticoids have the following well-recognized adverse effects in infants4: irritability, gastrointestinal tract upset, appetite change, decreased growth while receiving treatment, fungal skin infection, hirsutism, cushingoid facies, hypertension, pneumocystis pneumonia, and hypothalamic-pituitary-adrenal (HPA) axis suppression, a potentially devastating adverse effect, which in the appropriate clinical setting may lead to adrenal crisis.
AUTHOR INFORMATION
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED ARTICLE
Prevalence of Adrenal Insufficiency Following Systemic Glucocorticoid Therapy in Infants With Hemangiomas
Jefferson P. Lomenick, Kent L. Reifschneider, Anne W. Lucky, Denise Adams, Richard G. Azizkhan, Jessica G. Woo, and Philippe F. Backeljauw
Arch Dermatol. 2009;145(3):262-266.
ABSTRACT
| FULL TEXT
|